We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Philips and Corindus Join Forces in the Field of Advanced Robotic-Assisted Systems for Interventional Cardiology
News

Philips and Corindus Join Forces in the Field of Advanced Robotic-Assisted Systems for Interventional Cardiology

Philips and Corindus Join Forces in the Field of Advanced Robotic-Assisted Systems for Interventional Cardiology
News

Philips and Corindus Join Forces in the Field of Advanced Robotic-Assisted Systems for Interventional Cardiology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Philips and Corindus Join Forces in the Field of Advanced Robotic-Assisted Systems for Interventional Cardiology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Royal Philips Electronics and Corindus Inc. have announced an alliance agreement to add Corindus’ robotic-assisted system for the minimally invasive treatment of obstructed coronary arteries (also known as percutaneous coronary interventions) to Philips’ interventional cardiology solutions.

Corindus’ innovation focus on robotic-assisted systems for interventional cardiology procedures complements Philips’ expertise and leadership in interventional imaging and clinical informatics. As part of the alliance agreement, Philips has acquired a minority stake in Corindus. The financial terms of the agreement were not disclosed.

The trend towards image-guided minimally invasive interventions continues to grow, requiring image guidance and catheter controls that enable physicians to optimally perform their procedures.

Procedure innovation, driven by the combination of advanced imaging tools, new interventional devices and improved delivery controls, is aimed at simplifying the procedures and facilitating instantly informed decision making, while further reducing discomfort to the patient and the physician.

“Personalized and less invasive treatments are the way forward in patient care,” said Steve Rusckowski, CEO for Philips Healthcare. “As part of our strategy, Philips is committed to delivering integrated interventional solutions for image-guided minimally invasive procedures by working closely with hospitals and industrial partners in different application spaces. Corindus’ advanced interventional tool designed for percutaneous coronary interventions opens up further possibilities of reducing the strain on cardiologists, helping to advance patient care.”

“Everything in the catheterization lab, from X-ray imaging to coronary stents to contrast media, has advanced significantly over the past thirty years. However, the procedural process itself has remained largely unchanged,” said David Handler, President and CEO of Corindus.

Handler continued, “We are excited by the possibility of putting the power of remote precision robotic control into the hands of interventional cardiologists. Partnering with Philips will strengthen our ability to develop integrated technologies, with the ultimate objective of advancing interventional cardiology.”

Corindus’ CorPath 200 System* has been designed to provide precise, robotic-assisted placement of coronary guidewires and stent/balloon catheters in percutaneous coronary intervention (PCI) procedures.

In March of this year, Corindus announced that the first patients had been enrolled in its FDA approved CorPath PRECISE trial, which is expected to enlist 175 patients at leading medical centers across the United States. The results of this study will be the basis for a pre-market clearance 510(k) application to the FDA.

Advertisement